Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy
Sixty-seven percent of children with cerebral palsy (CCP) experience pain. Pain is closely interrelated to diminished quality of life. Despite this, pain is an overlooked and undertreated clinical problem. The objective of this study was to examine the analgesic effect of a single lower extremity in...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/14/1/43 |
| _version_ | 1797490028393267200 |
|---|---|
| author | Christian Wong Ian Westphall Josephine Sandahl Michelsen |
| author_facet | Christian Wong Ian Westphall Josephine Sandahl Michelsen |
| author_sort | Christian Wong |
| collection | DOAJ |
| description | Sixty-seven percent of children with cerebral palsy (CCP) experience pain. Pain is closely interrelated to diminished quality of life. Despite this, pain is an overlooked and undertreated clinical problem. The objective of this study was to examine the analgesic effect of a single lower extremity intramuscular injection of Abobotulinum toxin A/Dysport in CCP. Twenty-five CCP with at least moderate pain (r-FLACC ≥ 4) during passive range of motion were included. Localized pain and pain in everyday living were measured by r-FLACC and the Paediatric Pain Profile (PPP), respectively. Functional improvements were evaluated by the goal attainment scale (SMART GAS). Quality of life was evaluated by either the CPCHILD or the CP-QOL. The subjects were evaluated at baseline before injection, then after 4, 12, and 28 weeks. Twenty-two subjects had a significant mean and maximum localized pain reduction (<i>p</i> < 0.001) at four weeks post-treatment in 96% (21/22). The reduction was maintained at 12 (19/19) and 28 weeks (12/15). Daily pain evaluated by the PPP was significantly reduced and functional SMART GAS goals were significantly achieved from 4 to 28 weeks. Quality of life improved significantly at four weeks (CPCHILD). Significant functional gains and localized and daily pain reduction were seen from 4 to 28 weeks. |
| first_indexed | 2024-03-10T00:25:08Z |
| format | Article |
| id | doaj.art-d41bba6b77fe4507b07c18632b019ee8 |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-10T00:25:08Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-d41bba6b77fe4507b07c18632b019ee82023-11-23T15:36:09ZengMDPI AGToxins2072-66512022-01-011414310.3390/toxins14010043Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral PalsyChristian Wong0Ian Westphall1Josephine Sandahl Michelsen2Department of Orthopaedic Surgery, Copenhagen University Hospital, 2650 Hvidovre, DenmarkDepartment of Paediatrics, Copenhagen University Hospital, 2650 Hvidovre, DenmarkDepartment of Orthopaedic Surgery, Copenhagen University Hospital, 2650 Hvidovre, DenmarkSixty-seven percent of children with cerebral palsy (CCP) experience pain. Pain is closely interrelated to diminished quality of life. Despite this, pain is an overlooked and undertreated clinical problem. The objective of this study was to examine the analgesic effect of a single lower extremity intramuscular injection of Abobotulinum toxin A/Dysport in CCP. Twenty-five CCP with at least moderate pain (r-FLACC ≥ 4) during passive range of motion were included. Localized pain and pain in everyday living were measured by r-FLACC and the Paediatric Pain Profile (PPP), respectively. Functional improvements were evaluated by the goal attainment scale (SMART GAS). Quality of life was evaluated by either the CPCHILD or the CP-QOL. The subjects were evaluated at baseline before injection, then after 4, 12, and 28 weeks. Twenty-two subjects had a significant mean and maximum localized pain reduction (<i>p</i> < 0.001) at four weeks post-treatment in 96% (21/22). The reduction was maintained at 12 (19/19) and 28 weeks (12/15). Daily pain evaluated by the PPP was significantly reduced and functional SMART GAS goals were significantly achieved from 4 to 28 weeks. Quality of life improved significantly at four weeks (CPCHILD). Significant functional gains and localized and daily pain reduction were seen from 4 to 28 weeks.https://www.mdpi.com/2072-6651/14/1/43painmusculoskeletal paincerebral palsychildrenBotulinum toxins type A |
| spellingShingle | Christian Wong Ian Westphall Josephine Sandahl Michelsen Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy Toxins pain musculoskeletal pain cerebral palsy children Botulinum toxins type A |
| title | Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy |
| title_full | Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy |
| title_fullStr | Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy |
| title_full_unstemmed | Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy |
| title_short | Measuring Effects on Pain and Quality of Life after Abobotulinum Toxin A Injections in Children with Cerebral Palsy |
| title_sort | measuring effects on pain and quality of life after abobotulinum toxin a injections in children with cerebral palsy |
| topic | pain musculoskeletal pain cerebral palsy children Botulinum toxins type A |
| url | https://www.mdpi.com/2072-6651/14/1/43 |
| work_keys_str_mv | AT christianwong measuringeffectsonpainandqualityoflifeafterabobotulinumtoxinainjectionsinchildrenwithcerebralpalsy AT ianwestphall measuringeffectsonpainandqualityoflifeafterabobotulinumtoxinainjectionsinchildrenwithcerebralpalsy AT josephinesandahlmichelsen measuringeffectsonpainandqualityoflifeafterabobotulinumtoxinainjectionsinchildrenwithcerebralpalsy |